Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385311 | 0.79 | HDAC1 (0.47) | HDAC1HDAC6MEN1KMT2ACYP1A2 | |
| SCHEMBL4886159 | 0.78 | KMT2A (0.44) | CES1APPHDAC1HDAC6MEN1 | |
| SCHEMBL8119143 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AMAOAMAOBCYP1A2 | |
| SCHEMBL20989804 | 0.78 | APP (0.52) | CES2CES1APPHDAC8CYP3A4 | |
| SCHEMBL1120958 | 0.75 | MTNR1A (0.42) | CES2CES1APPMEN1KMT2A | |
| SCHEMBL16334900 | 0.75 | CES1 (0.49) | CES2CES1APPMEN1KMT2A | |
| SCHEMBL8034298 | 0.74 | CRHR1 (0.41) | CES2CES1APPL3MBTL1 | |
| SCHEMBL1120983 | 0.74 | CES2 (0.35) | CES2CES1APPHDAC8KMT2A | |
| SCHEMBL1120955 | 0.74 | MAPT (0.40) | APPHDAC8CYP2D6 | |
| SCHEMBL18754204 | 0.72 | MAPT (0.43) | APPMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727912-B1 | CRYSTALS OF GLYCINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2017-04-19 | — | — | EP | disclosed |
| CN-103619823-B | The crystal of glycine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2016-01-20 | — | — | CN | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9006434-B2 | Crystals of glycine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20140128605-A1 | CRYSTALS OF GLYCINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2727912-A1 | CRYSTALS OF GLYCINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-103619823-A | Crystals of glycine derivative and pharmaceutical use thereof | TORAY INDUSTRIES | 2014-03-05 | — | — | CN | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2042171-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | Toray Industries, Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039687-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | Toray Industries, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2039687-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | Toray Industries, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| CN-101128436-A | Glycine derivative and use thereof | TORAY INDUSTRIES (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1840121-A1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128605-A1 | CRYSTALS OF GLYCINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | PEPD, GLS, SLC6A5 | CES2 2850/4885CES1 3454/4885APP 993/4885 |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | CES2 3942/4885CES1 3595/4885APP 912/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | CES2 4720/4885CES1 2010/4885APP 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.